Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. has shown a notable increase in revenue, reporting $422K in Q2, up from $197K in Q1, indicating a positive upward trend for the company. Forecasts suggest strong revenue growth potential, with expectations of reaching $1.3 million in 2025 and $4.5 million in 2026. As a clinical-stage biopharmaceutical company, RenovoRx is addressing high unmet medical needs in cancer treatment, which bolsters the outlook for future financial performance driven by its innovative therapies.

Bears say

RenovoRx Inc reported revenue of $0.4 million alongside a net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08), which aligned with consensus estimates but highlights the ongoing financial vulnerability of the company. The company's focus on developing therapies for pancreatic cancer faces significant challenges, given the disease's bleak 5-year overall survival rate of just 12%, potentially limiting market adoption and revenue generation. Additionally, while there are prospects for growth within the biopharmaceutical sector, the inherent risks associated with clinical-stage companies such as RenovoRx raise concerns about future financial stability and investor confidence.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.